In preclinical trials, ST3-H2A2 was found toinhibit STAT-3 N-terminal domain, resulting in the blockage of STAT-3dimerization and apoptosis in prostate cancer cell lines (Timofeeva et al., 2013). This evidence concerns the gene STAT3 and prostate carcinoma.